Glucose transporter‑1 inhibition overcomes imatinib resistance in gastrointestinal stromal tumor cells

Shima,Takafumi; Taniguchi,Kohei; Tokumaru,Yoshihisa; Inomata,Yosuke; Arima,Jun; Lee,Sang-Woong; Takabe,Kazuaki; Yoshida,Kazuhiro; Uchiyama,Kazuhisa

doi:10.3892/or.2021.8218

Glucose transporter‑1 inhibition overcomes imatinib resistance in gastrointestinal stromal tumor cells

Authors:
- Takafumi Shima
- Kohei Taniguchi
- Yoshihisa Tokumaru
- Yosuke Inomata
- Jun Arima
- Sang-Woong Lee
- Kazuaki Takabe
- Kazuhiro Yoshida
- Kazuhisa Uchiyama
View Affiliations

Affiliations: Department of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569‑8686, Japan, Breast Surgery, Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA, Department of Surgical Oncology, Graduate School of Medicine, Gifu University, Gifu, Gifu 501‑1194, Japan
Published online on: November 4, 2021 https://doi.org/10.3892/or.2021.8218
Article Number: 7
Copyright: © Shima et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Imatinib mesylate (imatinib) is the primary agent of choice used to treat gastrointestinal stromal tumors (GIST). However, drug resistance to imatinib poses a major obstacle to treatment efficacy. In addition, the relationship between imatinib resistance and glycolysis is poorly understood. Glucose transporter (GLUT)‑1 is a key component of glycolysis. The present study aimed to assess the potential relationship between components in the glycolytic pathway and the acquisition of imatinib resistance by GIST cells, with particular focus on GLUT‑1. An imatinib‑resistant GIST cell line was established through the gradual and continuous imatinib treatment of the parental human GIST cell line GIST‑T1. The expression of glycolysis‑related molecules (GLUT‑1, hexokinase 2, pyruvate kinase M2 and lactate dehydrogenase) was assessed in parental and imatinib‑resistant cells by western blotting, reverse transcription‑quantitative PCR and glucose and lactate measurement kits. In addition, clinical information and transcriptomic data obtained from the gene expression omnibus database (GSE15966) were used to confirm the in vitro results. The potential effects of GLUT‑1 inhibition on the expression of proteins in the glycolysis (GLUT‑1, hexokinase 2, pyruvate kinase M2 and lactate dehydrogenase) and apoptosis pathways (Bcl‑2, cleaved PARP, caspase-3 and caspase-9) in imatinib‑resistant cells were then investigated following gene silencing and treatment using the GLUT‑1 inhibitor WZB117 by western blotting. For gene silencing, the mature siRNAs for SLC2A1 were used for cell transfection. Annexin V‑FITC/PI double‑staining followed by flow cytometry was used to measure apoptosis whereas three‑dimensional culture experiments were used to create three‑dimensional spheroid cells where cell viability and spheroid diameter were measured. Although imatinib treatment downregulated GLUT‑1 expression and other glycolysis pathway components hexokinase 2, pyruvate kinase M2, and lactate dehydrogenase in parental GIST‑T1 cells even at low concentrations. By contrast, expression of these glycolysis pathway components in imatinib‑resistant cells were increased by imatinib treatment. WZB117 administration significantly downregulated AKT phosphorylation and Bcl‑2 expression in imatinib‑resistant cells, whereas the combined administration of imatinib and WZB117 conferred synergistic growth inhibition effects in apoptosis assay. WZB117 was found to exert additional inhibitory effects by inducing apoptosis in imatinib‑resistant cells. Therefore, the present study suggests that GLUT‑1 is involved in the acquisition of imatinib resistance by GIST cells, which can be overcome by combined treatment with WZB117 and imatinib.

View Figures

View References

1	Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P and Demetri G: Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 3:655–664. 2002. View Article : Google Scholar : PubMed/NCBI
2	Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A and Bulusu VR: Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. 40:39–46. 2016. View Article : Google Scholar : PubMed/NCBI
3	Milhem M and Deutsch JM: Imatinib dosing in gastrointestinal stromal tumors (GISTs): When, how much, and how long? Curr Clin Pharmacol. 10:311–320. 2015. View Article : Google Scholar : PubMed/NCBI
4	Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, et al: Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 26:620–625. 2008. View Article : Google Scholar : PubMed/NCBI
5	Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, et al: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 26:626–632. 2008. View Article : Google Scholar : PubMed/NCBI
6	Lunt SY and Vander Heiden MG: Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 27:441–464. 2011. View Article : Google Scholar : PubMed/NCBI
7	Mazurek S: Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol. 43:969–980. 2011. View Article : Google Scholar : PubMed/NCBI
8	Taniguchi K, Uchiyama K and Akao Y: PTBP1-targeting microRNAs regulate cancer-specific energy metabolism through the modulation of PKM1/M2 splicing. Cancer Sci. 112:41–50. 2020. View Article : Google Scholar : PubMed/NCBI
9	Akram M: Mini-review on glycolysis and cancer. J Cancer Educ. 28:454–457. 2013. View Article : Google Scholar : PubMed/NCBI
10	Warburg O: The metabolism of carcinoma cells. J Cancer Res. 9:148–163. 1925. View Article : Google Scholar
11	Warburg O: On the origin of cancer cells. Science. 123:309–314. 1936. View Article : Google Scholar : PubMed/NCBI
12	Flavahan WA, Wu Q, Hitomi M, Rahim N, Kim Y, Sloan AE, Weil RJ, Nakano I, Sarkaria JN, Stringer BW, et al: Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci. 16:1373–1382. 2013. View Article : Google Scholar : PubMed/NCBI
13	Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, et al: A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther. 11:1672–1682. 2012. View Article : Google Scholar : PubMed/NCBI
14	Gupta A, Ajith A, Singh S, Panday RK, Samaiya A and Shukla S: PAK2-c-Myc-PKM2 axis plays an essential role in head and neck oncogenesis via regulating Warburg effect. Cell Death Dis. 9:8252018. View Article : Google Scholar : PubMed/NCBI
15	Huang X, Gan G, Wang X, Xu T and Xie W: The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance. Autophagy. 15:1258–1279. 2019. View Article : Google Scholar : PubMed/NCBI
16	Vander Heiden MG: Targeting cancer metabolism: A therapeutic window opens. Nat Rev Drug Discov. 10:671–684. 2011. View Article : Google Scholar : PubMed/NCBI
17	Macheda ML, Rogers S and Best JD: Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 202:654–662. 2005. View Article : Google Scholar : PubMed/NCBI
18	Olson AL and Pessin JE: Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. Annu Rev Nutr. 16:235–256. 1996. View Article : Google Scholar : PubMed/NCBI
19	Chen Q, Meng YQ, Xu XF and Gu J: Blockade of GLUT1 by WZB117 resensitizes breast cancer cells to adriamycin. Anticancer Drugs. 28:880–887. 2017. View Article : Google Scholar : PubMed/NCBI
20	Cho MH, Park CK, Park M, Kim WK, Cho A and Kim H: Clinicopathologic features and molecular characteristics of glucose metabolism contributing to ¹⁸F-fluorodeoxyglucose uptake in gastrointestinal stromal tumors. PLoS One. 10:e01414132015. View Article : Google Scholar : PubMed/NCBI
21	Berlth F, Mönig S, Pinther B, Grimminger P, Maus M, Schlösser H, Plum P, Warnecke-Eberz U, Harismendy O, Drebber U, et al: Both GLUT-1 and GLUT-14 are independent prognostic factors in gastric adenocarcinoma. Ann Surg Oncol. 22 (Suppl 3):S822–S831. 2015. View Article : Google Scholar : PubMed/NCBI
22	Wang YD, Li SJ and Liao JX: Inhibition of glucose transporter 1 (GLUT1) chemosensitized head and neck cancer cells to cisplatin. Technol Cancer Res Treat. 12:525–535. 2013. View Article : Google Scholar : PubMed/NCBI
23	Abouzeid AH, Patel NR, Rachman IM, Senn S and Torchilin VP: Anti-cancer activity of anti-GLUT1 antibody-targeted polymeric micelles co-loaded with curcumin and doxorubicin. J Drug Target. 21:994–1000. 2013. View Article : Google Scholar : PubMed/NCBI
24	Huang WK, Gao J, Chen Z, Shi H, Yuan J, Cui HL, Yeh CN, Bränström R, Larsson C, Li S, et al: Heterogeneity of metabolic vulnerability in imatinib-resistant gastrointestinal stromal tumor. Cells. 9:13332020. View Article : Google Scholar : PubMed/NCBI
25	Xu K, He Z, Chen M, Wang N, Zhang D, Yang L, Xu Z and Xu H: HIF-1α regulates cellular metabolism, and imatinib resistance by targeting phosphogluconate dehydrogenase in gastrointestinal stromal tumors. Cell Death Dis. 11:5862020. View Article : Google Scholar : PubMed/NCBI
26	Kominsky DJ, Klawitter J, Brown JL, Boros LG, Melo JV, Eckhardt SG and Serkova NJ: Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Clin Cancer Res. 15:3442–3450. 2009. View Article : Google Scholar : PubMed/NCBI
27	Li J, Dang Y, Gao J, Li Y, Zou J and Shen L: PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs). Med Oncol. 32:1112015. View Article : Google Scholar : PubMed/NCBI
28	Tauchi T, Sumi M, Nakajima A, Sashida G, Shimamoto T and Ohyashiki K: BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Clin Cancer Res. 9:4267–4273. 2003.PubMed/NCBI
29	Rozeboom B, Dey N and De P: ER⁺ metastatic breast cancer: Past, present, and a prescription for an apoptosis-targeted future. Am J Cancer Res. 9:2821–2831. 2019.PubMed/NCBI
30	Bai F, Yu Z, Gao X, Gong J, Fan L and Liu F: Simvastatin induces breast cancer cell death through oxidative stress up-regulating miR-140-5p. Aging (Albany NY). 11:3198–3219. 2019. View Article : Google Scholar : PubMed/NCBI
31	Goldar S, Khaniani MS, Derakhshan SM and Baradaran B: Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev. 16:2129–2144. 2015. View Article : Google Scholar : PubMed/NCBI
32	Taguchi T, Sonobe H, Toyonaga S, Yamasaki I, Shuin T, Takano A, Araki K, Akimaru K and Yuri K: Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor. Lab Invest. 82:663–665. 2002. View Article : Google Scholar : PubMed/NCBI
33	Kawaguchi N, Tashiro K, Taniguchi K, Kawai M, Tanaka K, Okuda J, Hayashi M and Uchiyama K: Nogo-B (Reticulon-4B) functions as a negative regulator of the apoptotic pathway through the interaction with c-FLIP in colorectal cancer cells. Biochim Biophys Acta Mol Basis Dis. 1864:2600–2609. 2018. View Article : Google Scholar : PubMed/NCBI
34	Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55. 1984. View Article : Google Scholar : PubMed/NCBI
35	Li YL, Weng HC, Hsu JL, Lin SW, Guh JH and Hsu LC: The combination of MK-2206 and WZB117 exerts a synergistic cytotoxic effect against breast cancer cells. Front Pharmacol. 10:13112019. View Article : Google Scholar : PubMed/NCBI
36	Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
37	Taniguchi K, Wada SI, Ito Y, Hayashi J, Inomata Y, Lee SW, Tanaka T, Komura K, Akao Y, Urata H and Uchiyama K: α-Aminoisobutyric acid-containing amphipathic helical peptide-cyclic RGD conjugation as a potential drug delivery system for microRNA replacement therapy in vitro. Mol Pharm. 16:4542–4550. 2019. View Article : Google Scholar : PubMed/NCBI
38	Matsuo K, Taniguchi K, Hamamoto H, Ito Y, Futaki S, Inomata Y, Shima T, Asakuma M, Lee SW, Tanaka K, et al: Delta-like 3 localizes to neuroendocrine cells and plays a pivotal role in gastrointestinal neuroendocrine malignancy. Cancer Sci. 110:3122–3131. 2019. View Article : Google Scholar : PubMed/NCBI
39	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
40	Rink L, Skorobogatko Y, Kossenkov AV, Belinsky MG, Pajak T, Heinrich MC, Blanke CD, von Mehren M, Ochs MF, Eisenberg B and Godwin AK: Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor. Mol Cancer Ther. 8:2172–2182. 2009. View Article : Google Scholar : PubMed/NCBI
41	Ojelabi OA, Lloyd KP, Simon AH, De Zutter JK and Carruthers A: WZB117 (2-Fluoro-6-(m-hydroxybenzoyloxy) Phenyl m-Hydroxybenzoate) inhibits GLUT1-mediated sugar transport by binding reversibly at the exofacial sugar binding site. J Biol Chem. 291:26762–26772. 2016. View Article : Google Scholar : PubMed/NCBI
42	Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, et al: Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381:295–302. 2013. View Article : Google Scholar : PubMed/NCBI
43	Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 347:472–480. 2002. View Article : Google Scholar : PubMed/NCBI
44	Matsumoto K, Sawaki A, Mizuno N, Hara K, Hijioka S, Niwa Y, Tajika M, Kawai H, Kondo S and Yamao K: Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor. Jpn J Clin Oncol. 41:57–62. 2011. View Article : Google Scholar : PubMed/NCBI
45	Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, et al: Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 11:4182–4190. 2005. View Article : Google Scholar : PubMed/NCBI
46	Vitiello GA, Medina BD, Zeng S, Bowler TG, Zhang JQ, Loo JK, Param NJ, Liu M, Moral AJ, Zhao JN, et al: Mitochondrial inhibition augments the efficacy of imatinib by resetting the metabolic phenotype of gastrointestinal stromal tumor. Clin Cancer Res. 24:972–984. 2018. View Article : Google Scholar : PubMed/NCBI
47	Tarn C, Skorobogatko YV, Taguchi T, Eisenberg B, von Mehren M and Godwin AK: Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. Cancer Res. 66:5477–5486. 2006. View Article : Google Scholar : PubMed/NCBI
48	Liu W, Fang Y, Wang XT, Liu J, Dan X and Sun LL: Overcoming 5-Fu resistance of colon cells through inhibition of Glut1 by the specific inhibitor WZB117. Asian Pac J Cancer Prev. 15:7037–7041. 2014. View Article : Google Scholar : PubMed/NCBI
49	Erber J, Steiner JD, Isensee J, Lobbes LA, Toschka A, Beleggia F, Schmitt A, Kaiser RWJ, Siedek F, Persigehl T, et al: Dual inhibition of GLUT1 and the ATR/CHK1 kinase axis displays synergistic cytotoxicity in KRAS-mutant cancer cells. Cancer Res. 79:4855–4868. 2019. View Article : Google Scholar : PubMed/NCBI
50	Shalinsky DR, Slovak ML and Howell SB: Modulation of vinblastine sensitivity by dipyridamole in multidrug resistant fibrosarcoma cells lacking mdr1 expression. Br J Cancer. 64:705–709. 1991. View Article : Google Scholar : PubMed/NCBI
51	Pelicano H, Martin DS, Xu RH and Huang P: Glycolysis inhibition for anticancer treatment. Oncogene. 25:4633–4646. 2006. View Article : Google Scholar : PubMed/NCBI
52	Melstrom LG, Salabat MR, Ding XZ, Milam BM, Strouch M, Pelling JC and Bentrem DJ: Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas. 37:426–431. 2008. View Article : Google Scholar : PubMed/NCBI
53	Hu Y, Yang Z, Bao D, Ni JS and Lou J: miR-455-5p suppresses hepatocellular carcinoma cell growth and invasion via IGF-1R/AKT/GLUT1 pathway by targeting IGF-1R. Pathol Res Pract. 215:1526742019. View Article : Google Scholar : PubMed/NCBI
54	Wu XL, Wang LK, Yang DD, Qu M, Yang YJ, Guo F, Han L and Xue J: Effects of Glut1 gene silencing on proliferation, differentiation, and apoptosis of colorectal cancer cells by targeting the TGF-β/PI3K-AKT-mTOR signaling pathway. J Cell Biochem. 119:2356–2367. 2018. View Article : Google Scholar : PubMed/NCBI
55	Farahani RM and Xaymardan M: Platelet-derived growth factor receptor alpha as a marker of mesenchymal stem cells in development and stem cell biology. Stem Cells Int. 2015:3627532015. View Article : Google Scholar : PubMed/NCBI
56	Heldin CH, Ostman A and Rönnstrand L: Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta. 1378:F79–F113. 1998.PubMed/NCBI
57	Heilig CW, Deb DK, Abdul A, Riaz H, James LR, Salameh J and Nahman NS Jr: GLUT1 regulation of the pro-sclerotic mediators of diabetic nephropathy. Am J Nephrol. 38:39–49. 2013. View Article : Google Scholar : PubMed/NCBI